Delcath Systems to Host First Quarter 2022 Results
April 28 2022 - 9:00AM
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
company focused on the treatment of primary and metastatic cancers
of the liver, announced today it will host a conference call on May
10, 2022, at 8:30 AM Eastern Time to discuss results for its first
quarter ended March 31, 2022.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes
before the beginning of the call.
Event Date: Tuesday, May 10, 2022Time: 8:30 AM Eastern
TimeParticipant Numbers: Toll Free: 877-545-0523; Participant
Access Code: 633971International: 973-528-0016 Participant Access
Code: 633971Webcast:
https://www.webcaster4.com/Webcast/Page/2475/45401
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company’s proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the PHP system is being developed
under the tradename HEPZATO KIT (melphalan hydrochloride for
injection/hepatic delivery system), or HEPZATO, for the treatment
of metastatic ocular melanoma (mOM), also known as metastatic uveal
melanoma (mUM) and is considered a combination drug and device
product regulated by the United States Food and Drug Administration
(FDA).
In Europe, the PHP system is now regulated as a Class lll
medical device and is approved for sale under the trade name
CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where
it has been used at major medical centers to treat a wide range of
cancers of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James
Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jul 2023 to Jul 2024